Home > Insider Trading > Filing (0001209191-22-060588)

Filing Details

Accession Number:: 0001209191-22-060588
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2022-12-09 19:41:23
Reporting Period:: 2022-12-06

Accepted Time:: 2022-12-09 19:41:23
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
25743	Therapeuticsmd Inc.	TXMD	Pharmaceutical Preparations (2834)	870233535

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1532233	Brian Bernick	951 Yamato Road Suite 220 Boca Raton FL 33431	Co-Chief Executive Officer	No	Yes	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Acquisiton	2022-12-06	3,167	$0.00	5,127	No	4	M	Direct
Common Stock	Disposition	2022-12-06	935	$4.92	4,192	No	4	S	Direct
Common Stock	Disposition	2022-12-09	320	$6.31	3,872	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	M	Direct
No	4	S	Direct
No	4	S	Direct

Reported Derivative Transactions

Show Other Fields >>

Sec. Name	Sec. Type	Acquisiton - Disposition	Date	Amount	Price	Amount - 2	Price - 2
Common Stock	Restricted Stock Units	Disposition	2022-12-06	3,167	$0.00	3,167	$0.00

Remaning Holdings	Exercise Date	Expiration Date	Equity Swap Involved	Transaction Form Type	Transaction Code	Nature of Ownership
10,517			No	4	M	Direct

Reported Non-Derivative Holdings

Sec. Name	Remaning Holdings	Nature of Ownership	Explanation
Common Stock	35,147	Indirect	See Footnote
Common Stock	60	Indirect	See Footnote

Footnotes

Each restricted stock unit ("RSU") represents a contingent right to receive one share of issuer common stock upon settlement. On December 6, 2022, the reporting person received 3,167 shares of issuer common stock in settlement of restricted stock units (RSUs).
The reported securities represent shares of issuer common stock sold upon settlement to satisfy tax obligations
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $4.66 to $5.37, inclusive. The reporting person undertakes to provide to TherapeuticsMD, Inc., any security holder of TherapeuticsMD, Inc., or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth.
The reported securities are owned by BF Investment Enterprises, Ltd. ("BF Investment"). The reporting person (i) holds, together with his spouse as tenants by the entirety, a 70.6% membership interest in BF Management, LLC (the "GP"), the general partner of BF Investment, (ii) holds, together with his spouse as tenants by the entirety, a 73% limited partner interest in BF Investment, (iii) holds in the aggregate, with his spouse in their individual capacities, 3.272% limited partner interest in BF Investment, and (iv) serves as the Manager of the GP. The reporting person disclaims beneficial ownership of the reported securities except to the extent of his pecuniary interest therein.
The reported securities are owned by the GP. As disclosed in Footnote 4 above, the reporting person, together with his spouse as tenants by the entirety, holds a 70.6% membership interest in the GP. The reporting person disclaims beneficial ownership of the reported securities held by the GP, except to the extent of his pecuniary interest therein.
The RSUs shall vest as as follows: 5,200 RSUs shall vest in three equal installments annually beginning on March 23, 2023; 1,664 RSUs shall vest in three equal installments annually beginning on September 29, 2022; 3,200 RSUs shall vest in two equal installments annually beginning on July 1, 2023; and 1,010 RSUs shall vest on March 30, 2023. Also includes 2,610 RSUs that were previously vested but were not settled until December 6, 2022.